Omeros Corporation (OMER) News
Filter OMER News Items
OMER News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OMER News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OMER News From Around the Web
Below are the latest news stories about OMEROS CORP that investors may wish to consider to help them evaluate OMER as an investment opportunity.
When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?With the business potentially at an important milestone, we thought we'd take a closer look at Omeros Corporation's... |
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock SurgesAcross various trials, narsoplimab has shown no safety signals of concern. |
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMASEATTLE, December 19, 2024--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). T |
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial ChallengesWe recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going to take a look at where Omeros Corporation (NASDAQ:OMER) stands against other stocks under Jim Cramer’s lightning rounds’ spotlight. Jim Cramer, host of Mad Money, recently discussed the outlook for the stock market following […] |
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingSEATTLE, December 10, 2024--Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual Meeting of the American Society of Hematology (ASH) yesterday in San Diego. The posters, both addressing zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening hematological disorder – |
Omeros Corporation Announces Upcoming Presentations at ASH Annual MeetingSEATTLE, December 02, 2024--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening he |
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on NewsOmeros announced steps toward resubmitting its biologics license application |
Omeros Corporation Provides Update on Progress Toward BLA ResubmissionSEATTLE, November 21, 2024--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application ("BLA") for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy ("TA-TMA"). In last week’s quarterly earnings release and associated call, Omeros stated that it was awaiting feedbac |
Q3 2024 Omeros Corp Earnings CallQ3 2024 Omeros Corp Earnings Call |
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial AdjustmentsOmeros Corp (OMER) reports reduced net loss and strategic progress in clinical programs, despite financial challenges and market competition. |